Disease-modifying antirheumatic drugs (DMARDs) comprise a category of otherwise unrelated disease-modifying drugs defined by their use in rheumatoid
Pages in category Disease-modifying antirheumatic drugs ; Disease-modifying antirheumatic drug ; A. Abatacept Adalimumab Anakinra Apremilast Auranofin
Drugs currently authorised as of December 2024 for use in psoriatic arthritis. bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DMARD, disease-modifying antirheumatic drug; IL, interleukin; JAK, Janus kinase; PDE4, phosphodiesterase
Disease-modifying antirheumatic drug Methotrexate Hydroxychloroquine Auranofin
disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum
Disease-Modifying Antirheumat Drugs Misc, Disease-Modifying Antirheumatic Drugs, Diuretics, Dopamine Precursors, Dopamine Receptor Agonists, Eent Drugs
Conventional systemic Disease Modifying Antirheumatic drugs (csDMARDS) are viewed as disease-modifying drugs. They include Methotrexate, Sulfasalazine
Antirheumatics, or what we now call disease-modifying antirheumatic drugs (DMARDs) were established as treatments for rheumatic diseases starting with
Disease-modifying antirheumatic drugs (DMARDs) comprise a category of otherwise unrelated disease-modifying drugs defined by their use in rheumatoid arthritis
Comments
Boyd